Pacira Pharmaceuticals Inc (PCRX) Key Ratios

$26.55

up-down-arrow $-0.05 (-0.19%)

As on 04-Sep-2026 12:37EDT

Market cap

info icon

$1,014 Mln

Revenue (TTM)

info icon

$746 Mln

P/E Ratio

info icon

73.6

P/B Ratio

info icon

1.5

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 8.47 6.24 5.71 3.69 8.20
EBIT -47.39 124.13 132.42 4.74 -18.60
Net Profit 59.57 196.00 111.48 73.30 -39.05
EPS 61.98 208.29 112.46 60.00 -38.38
Book Value -- -- 1.59 -1.53 3.08
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 2.986.413.974.33-7.09
Net Margin info --7.781.96----
Return on equity info -2.010.462.140.96-12.08
Return on Capital info -1.190.03--0.55-6.93
Return on Assets info -1.100.010.910.50-6.37
Debt to Equity (x) info ----0.540.660.82
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
--
0.55
-6.93
2.80
0.94
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

2.14

Lower than Peers by 16.83

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
2.14
0.96
-12.08
5.10
2.11
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

0.91

Lower than Peers by 1.95

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
0.91
0.50
-6.37
2.58
0.85
Peer Median
2.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

3.97

Lower than Peers by 11.85

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
3.97
4.33
-7.09
11.71
7.33
Peer Median
15.82
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

1.96

Lower than Peers by 6.27

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
1.96
0.97
-14.20
6.22
2.39
Peer Median
8.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

5.71

Lower than Peers by 2.34

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
5.71
0.04
0.04
0.01
0.23
Peer Median
8.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

132.42

Higher than Peers by 124.16

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
132.42
163.38
-162.86
61.65
-42.77
Peer Median
8.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

111.48

Higher than Peers by 103.75

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
111.48
107.07
-337.30
163.72
-62.10
Peer Median
7.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

112.46

Higher than Peers by 102.06

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
112.46
1.08
-3.52
1.32
-0.63
Peer Median
10.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

0.03

Lower than Peers by 4.84

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
0.03
--
--
--
--
Peer Median
4.87
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.54

Lower than Peers by 0.05

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
0.54
0.66
0.82
0.67
0.99
Peer Median
0.59
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.02

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
0.02
0.01
0.27
0.02
0.06
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

5.04

Higher than Peers by 3.39

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
5.04
4.54
2.40
5.24
3.37
Peer Median
1.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.94

Higher than Peers by 2.74

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
3.94
3.28
2.00
4.17
2.72
Peer Median
1.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

2.28

Lower than Peers by 2.49

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
2.28
2.16
-3.00
4.56
1.37
Peer Median
4.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

17.75

Lower than Peers by 3.53

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
17.75
17.08
16.16
15.64
14.76
Peer Median
21.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.46

Higher than Peers by 0.06

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
0.46
0.52
0.45
0.41
0.36
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
--
59.68
57.02
55.18
53.33
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
--
339.21
246.07
198.20
178.33
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
--
41.81
37.32
30.58
23.61
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
--
357.08
265.77
222.80
208.05
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

73.60

Higher than Peers by 36.28

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
73.60
158.14
-9.28
41.87
111.35
Peer Median
37.32
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

1.53

Lower than Peers by 6.22

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
1.53
1.60
1.19
2.02
2.29
Peer Median
7.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
--
--
--
--
--
Peer Median
0.50
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

10.26

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
10.26
10.84
37.02
13.35
16.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

1,014

Lower than Peers by 1,507

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Pacira Pharmaceuticals Inc (PCRX)
1,014
--
--
--
--
Peer Median
2,521
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...